AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OPTHEA LTD

0.014

-0.002-12.50%

Volume:254.01M

Turnover:3.45M

Market Cap:19.15M

PE:0.03

High:0.015

Open:0.015

Low:0.012

Close:0.016

52wk High:0.600

52wk Low:0.012

Shares:1.37B

Float Shares:786.04M

Volume Ratio:2.42

T/O Rate:32.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.414

EPS(LYR):-0.186

ROE:-3383.08%

ROA:-50.44%

PB:0.57

PE(LYR):-0.08

Loading ...

Overview Company News Filings

BRIEF-Opthea To Recommence Trading On ASX On Or Around June 3, 2026

Opthea Poised to Resume Trading on Australian Securities Exchange After Decision to Advance Lung Disease Drug Candidate

MT Newswires Live

Opthea - to Recommence Trading on ASX on or Around June 3, 2026

THOMSON REUTERS

Opthea Ltd-Reinstatement to ASX and Update on Lam Development Program

THOMSON REUTERS

Opthea - Advances Opt-302 for Lymphangioleiomyomatosis (Lam)

THOMSON REUTERS

Opthea Swings to Fiscal H1 Earnings, Posts Lower Revenue, Plans to Rename

MT Newswires Live

Opthea Ltd H1 Net Income AUD 339.9 Million

THOMSON REUTERS

Opthea Begins Development Program To Investigate Potential Lymphangioleiomyomatosis Treatment Candidate

MT Newswires Live

Opthea Limited Issues New Options to Directors Under NED Plan

Opthea Limited unveils strategy to target rare lung disease LAM with OPT-302 relaunch

BNY Mellon Cuts Voting Power in Opthea to 6.37%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OPT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","market":"AU","secType":"STK","nameCN":"OPTHEA LTD","latestPrice":0.014,"timestamp":1780553520000,"preClose":0.016,"halted":0,"volume":254014622,"delay":0,"changeRate":-0.125,"nameEN":"OPTHEA LTD","floatShares":786037192,"shares":1367978173,"eps":0.4134704939041043,"marketStatus":"Not Yet Opened","change":-0.002,"latestTime":"06-04 16:12:00 AEST","open":0.015,"high":0.015,"low":0.012,"amount":3445132,"amplitude":0.1875,"askPrice":0.014,"askSize":2138166,"bidPrice":0.013,"bidSize":14763309,"shortable":3,"etf":0,"ttmEps":0.4134704939041043,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1780617600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.016,"openAndCloseTimeList":[[1780531200000,1780552800000]],"volumeRatio":2.4187436563867757,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"OPT.AU","preClose":0.016,"auctionPrice":0.014,"auctionVolume":11613877,"auction":3,"marketStatus":"盘后竞价","timestamp":1780553412198}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","floatShares":786037192,"roa":"-50.44%","roe":"-3383.08%","lyrEps":-0.186189,"volumeRatio":2.4187436563867757,"shares":1367978173,"dividePrice":0,"high":0.015,"amplitude":0.1875,"preClose":0.016,"low":0.012,"week52Low":0.012,"pbRate":"0.57","psRate":"-952.02","week52High":0.6,"institutionHeld":0,"latestPrice":0.014,"committee":0.746985,"eps":0.41352319747196437,"divideRate":0,"volume":254014622,"delay":0,"ttmEps":0.41352319747196437,"open":0.015,"prevYearClose":0.6,"prevWeekClose":0.6,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.6,"twentyDayClose":0.6,"sixtyDayClose":0.6,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OPT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640705922","title":"BRIEF-Opthea To Recommence Trading On ASX On Or Around June 3, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640705922","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640705922?lang=en_us&edition=fundamental","pubTime":"2026-06-03 09:16","pubTimestamp":1780449411,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea To Recommence Trading On ASX On Or Around June 3, 2026June 3 (Reuters) - Opthea Ltd OPT.AX:REINSTATEMENT TO ASX AND UPDATE ON LAM DEVELOPMENT PROGRAMTO RECOMMENCE TRADING ON ASX ON OR ARO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUE26MBYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","OPT.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640435921","title":"Opthea Poised to Resume Trading on Australian Securities Exchange After Decision to Advance Lung Disease Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2640435921","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640435921?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:33","pubTimestamp":1780443226,"startTime":"0","endTime":"0","summary":"Opthea (ASX:OPT) expects to resume trading on the Australian Securities Exchange on or around Wednesday following a decision to advance its OPT-302 drug candidate for the treatment of lymphangioleiomy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","OZR.AU","XAO.AU","XKO.AU","GIVE.AU","BEAR.AU","BBOZ.AU","GEAR.AU","SLF.AU","IISV.AU","STW.AU","EIGA.AU","XJO.AU","BK7067","ZYAU.AU","IMLC.AU","OZF.AU","VAS.AU","QFN.AU","IOZ.AU","E200.AU","QRE.AU","DACE.AU","IIGF.AU","VAP.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921854","title":"Opthea - to Recommence Trading on ASX on or Around June 3, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921854?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:48","pubTimestamp":1780440521,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUE26MBYV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640852921","title":"Opthea Ltd-Reinstatement to ASX and Update on Lam Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2640852921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640852921?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:48","pubTimestamp":1780440521,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUE26MBYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","OPT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640792185","title":"Opthea - Advances Opt-302 for Lymphangioleiomyomatosis (Lam)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640792185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640792185?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:48","pubTimestamp":1780440521,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUE26MBYV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","OPT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616992802","title":"Opthea Swings to Fiscal H1 Earnings, Posts Lower Revenue, Plans to Rename","url":"https://stock-news.laohu8.com/highlight/detail?id=2616992802","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616992802?lang=en_us&edition=fundamental","pubTime":"2026-03-02 13:16","pubTimestamp":1772428581,"startTime":"0","endTime":"0","summary":"Opthea (ASX:OPT) reported Monday fiscal first-half earnings of AU$0.2552 per share, compared to a loss of AU$0.1650 a year earlier.Revenue for the six months ended Dec. 31, 2025, was AU$1,000, compare","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OPT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616978871","title":"Opthea Ltd H1 Net Income AUD 339.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616978871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616978871?lang=en_us&edition=fundamental","pubTime":"2026-03-02 05:16","pubTimestamp":1772399762,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nPLXE92F98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OPT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607065544","title":"Opthea Begins Development Program To Investigate Potential Lymphangioleiomyomatosis Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2607065544","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607065544?lang=en_us&edition=fundamental","pubTime":"2026-01-30 09:16","pubTimestamp":1769735819,"startTime":"0","endTime":"0","summary":"Opthea (ASX:OPT) said it initiated a development program to investigate its OPT-302 treatment candidate for potentially treating lymphangioleiomyomatosis, starting with evaluating the feasibility of n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","OPT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593453935","title":"Opthea Limited Issues New Options to Directors Under NED Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2593453935","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593453935?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:50","pubTimestamp":1766440238,"startTime":"0","endTime":"0","summary":"Opthea Limited has issued 41,000,000 unquoted options to acquire fully paid ordinary shares to director Ms Katherine Connell. These options, expiring 11 November 2035, were granted under the Non-Executive Directors Share and Option Plan, as approved at the Annual General Meeting on 11 November 2025. No consideration was paid for the options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7bB3lC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","OPT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592953786","title":"Opthea Limited unveils strategy to target rare lung disease LAM with OPT-302 relaunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2592953786","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592953786?lang=en_us&edition=fundamental","pubTime":"2025-12-17 07:11","pubTimestamp":1765926674,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLbsgKJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589611806","title":"BNY Mellon Cuts Voting Power in Opthea to 6.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589611806","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589611806?lang=en_us&edition=fundamental","pubTime":"2025-12-08 05:29","pubTimestamp":1765142972,"startTime":"0","endTime":"0","summary":"The Bank of New York Mellon Corporation and its group entities have reported a change in their relevant interest in Opthea Limited, now holding 87,105,313 ordinary shares, representing a voting power of 6.37%. These shares are held as part of Opthea's ADR program, with ADR holders retaining their voting rights.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL3qdBgR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU0130102774.USD","BK7067","BK4588","LU1699723380.USD","LU1201861249.SGD","BK7508","OPT.AU","BK4135","LU0477156953.USD","LU1571399168.USD","LU0648001328.SGD","LU0130517989.USD","LU0980610538.SGD","BK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}